Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode

Authors

  • Sherrie Curtis,

    1. Process Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; telephone: 650-225-1000; fax: 650-225-6000
    Search for more papers by this author
  • Kitty Lee,

    1. Process Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; telephone: 650-225-1000; fax: 650-225-6000
    Search for more papers by this author
  • Gregory S. Blank,

    1. Process Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; telephone: 650-225-1000; fax: 650-225-6000
    Search for more papers by this author
  • Kurt Brorson,

    1. Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Dr., Bethesda, MD 20892
    Search for more papers by this author
  • Yuan Xu

    Corresponding author
    1. Process Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; telephone: 650-225-1000; fax: 650-225-6000
    2. Biopharmaceutical Process Development, Glaxo Smith Kline, Inc., 709 Swedeland Road UE 3839, King of Prussia, PA 19406; telephone: 610-270-7020; fax: 610-270-7449
    • Process Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; telephone: 650-225-1000; fax: 650-225-6000
    Search for more papers by this author

Abstract

The potential of viral contamination is a regulatory concern for continuous cell line-derived pharmaceutical proteins. Complementary and redundant safety steps, including an evaluation of the viral clearance capacity of unit operations in the purification process, are performed prior to registration and marketing of biotechnology pharmaceuticals. Because process refinement is frequently beneficial, CBER/FDA has published guidance facilitating process improvement by delineating specific instances where the bracketing and generic approaches are appropriate for virus removal validation. In this study, a generic/matrix study was performed using Q-Sepharose Fast Flow (QSFF) chromatography to determine if bracketing and generic validation can be applied to anion exchange chromatography. Key operational parameters were varied to upper and lower extreme values and the impact on viral clearance was assessed using simian virus 40 (SV40) as the model virus. Operational ranges for key chromatography parameters were identified where an SV40 log10 reduction value (LRV) of ≥4.7 log10 is consistently achieved. On the basis of the apparent robustness of SV40 removal by Q-anion exchange chromatography, we propose that the concept of “bracketed generic” validation can be applied to this and potentially other chromatography unit operations. © 2003 Wiley Periodicals, Inc. Biotechnol Bioeng 84: 179–186, 2003.

Ancillary